Evaluating heart health in adult cancer patients treated with cardiotoxic therapies
Cardiovascular Health and Prognosis in Adult Patients With Cancer Exposed to Cardiotoxic Therapies, an Observational Study
This study is trying to see how heart health is affected in adult cancer patients who have received treatments that might harm their hearts.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Fondazione Policlinico Universitario Agostino Gemelli IRCCS Academic / other |
| Locations | 1 site (Rome, Lazio) |
| Trial ID | NCT06664528 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the cardiovascular health and prognosis of adult cancer patients who have been treated with potentially cardiotoxic therapies. The study will identify demographic factors associated with the onset of cardiotoxicity and determine which subgroups are more likely to experience major adverse cardiovascular events (MACE). Participants will undergo clinical, laboratory, and echocardiographic evaluations during their anticancer treatment, following current guidelines on Cardio-Oncology. The initial follow-up period for participants will be two years.
Who should consider this trial
Good fit: Ideal candidates for this study are adult patients over the age of 18 who are being treated with potentially cardiotoxic anticancer drugs.
Not a fit: Patients under the age of 18 or those unable to provide complete clinical data or follow-up information may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved monitoring and management of cardiovascular health in cancer patients receiving cardiotoxic therapies.
How similar studies have performed: Other studies have shown success in evaluating cardiovascular health in cancer patients, making this approach both relevant and necessary.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients over the age of 18 at the time of evaluation * Patients treated with potentially cardiotoxic anticancer drugs * Patients for which complete clinical, electrocardiographic and echocardiographic data are available at first evaluation and at least at one follow-up visit. Exclusion Criteria: * Patients under the age of 18 at the time of evaluation * Patients whose documentation of the first visit is not available * Patients for whom it is not possible to obtain follow-up information through a medical visit or by telephone * Patient with poor acoustic window for echocardiographic examination. * Refusal of informed consent to participate in the study.
Where this trial is running
Rome, Lazio
- Fondazione Policlinico Universitario A. Gemelli IRCCS;UOSD diagnostica cardiologica non invasiva — Rome, Lazio, Italy (Recruiting)
Study contacts
- Principal investigator: Antonella Lombardo — Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Study coordinator: Antonella Lombardo
- Email: antonella.lombardo@policlinicogemelli.it
- Phone: +390630157070
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.